Testimony & Briefings

NCHR Letter Concerning Lead in DC Public School Playground After lead was found in the playground at Janney Elementary School in Washington, DC, NCHR wrote a letter to DC Education Officials.
NCHR Public Comment to FDA on breast implant safety NCHR submitted a comment to the FDA regarding the safety of breast implants, making suggestions for patient checklists, registry changes, and more.
Cancer Prevention and Treatment Funds’ Comments On USPSTF Draft Recommendation Statement for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Cancer Prevention and Treatment Fund comments on USPSTF draft recommendation for BRCA related cancer risk assessment methods.
NCHR Comment on Management of Cybersecurity in Medical Devices March 18, 2019. Software and medical devices have become increasingly interconnected and vulnerable to cybersecurity breaches, which puts patients at risk. 
NCHR Testimony on the Evaluation for High-Risk HPV Detection Devices NCHR testified on March 8th, 2019 at the Microbiology Advisory Committee urging panel members to consider increasing HPV screening age from 25 to 30.
NCHR Statement to the Maryland State House Environmental Committee, Artificial Turf NCHR’s Jack Mitchell made a statement at the Maryland State House Environmental Committee regarding artificial turf and its negative effects.
Cancer Prevention and Treatment Funds’ Comments On USPSTF Draft Recommendation Statement for Breast Cancer: Medication Use to Reduce Risk CPTF comments on the USPSTF breast cancer medications such as tamoxifen and raloxifene that are used to reduce risk in patients.
NCHR Comments on USPSTF’s Draft Research Plan for Colorectal Cancer: Screening January 30, 2019. We strongly support the USPSTF’s efforts to update recommendations for different types of colorectal cancer screening for different demographic subgroups, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services.
Prepared Statement to the Greenwich Board of Estimate and Taxation Regarding Dangers of Artificial Turf, January 24, 2019 NCHR President Dr. Diana Zuckerman presented comments in Greenwich, CT regarding the possibility of artificial turf being used in their schools and fields.
NCHR Comment on FDA’s 510(k) Third Party Review Program Draft Guidance December 13, 2018. The third party review program clearly moves in the opposite direction, reducing patient safety, rather than protecting patients from potentially harmful devices.   We strongly oppose it for that reason.
NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.
NCHR Testimony to the FDA Patient Engagement Advisory Committee on Medical Devices November 15, 2019. NCHR testified to the FDA regarding social media surrounding medical devices, and how it affects patient engagement.
NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.
NCHR Testimony on the Opioid Sufentanil NCHR testifies against the approval of Sufentanil, a new sublingual opioid 10-15 times more potent than fentanyl.
NCHR Testimony of TIRF REMS August 3, 2018. TIRFs provide important options for cancer patients dealing with pain. However, we all know that they carry very serious risks and that’s why we need REMS that protect patients’ these risks.  These REMS are not working as well as the should to protect patients and need to be approved.
NCHR, NWHN, and OBOS Comments to USPSTF on Behavioral Weight Loss Interventions March 19, 2018. We support the USPSTF draft recommendation for behavior-based interventions for weight loss to prevent obesity-related health problems and death. We further support USPSTF’s efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more information becomes available, we encourage the re-evaluation and potential development of additional recommendation to improve the health of individuals with weight-related health concerns.
NCHR Comments to FDA on Nicotine Replacement Therapy (NRT) Product Uses and Labeling Changes February 15, 2018. It remains unclear whether individual achievement of abstinence is sustainable over time and whether long-term NRT use is more or less beneficial on an individual or population health level. We commend the FDA for addressing their role in developing strategies to evaluate NRT products and labeling. We agree that urgent action is necessary and the FDA should consider science-based approaches to reduce further harm from combustible tobacco products.
NCHR Comments on the USPSTF’s Evidence Review and Draft Recommendation Statement for Behavioral Counseling for Skin Cancer Prevention November 6, 2017. We support USPSTF’s draft recommendations for behavioral counseling interventions to prevent skin cancer as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more information becomes available, we encourage the provision of additional recommendations about more specific behavioral interventions to prevent skin cancer for individuals in various subgroups.
NCHR Letter to the DC City Council on Artificial Turf October 26, 2017. It is clear that city officials have assumed artificial turf products are safe because the salespeople told them they were safe. Unfortunately, there is clear scientific evidence that these materials are potentially harmful, and the only question is how harmful are they and how much exposure is likely to be harmful? Our children deserve better. 
NCHR Comments on the USPSTF’s Draft Recommendation Statement, Evidence Review, and Modeling Report on Cervical Cancer Screening October 9, 2017: The USPSTF proposes new cervical cancer screening recommendations. Surprisingly, the USPSTF proposes eliminating co-testing (pap and HPV test together) as a preferred screening approach in favor of the HPV test alone. Do the proposed recommendations deserve an “A” rating? Read our comments to find out.